Bone morphogenetic protein-4 interacts with activin and GnRH to modulate gonadotrophin secretion in LβT2 gonadotrophs

L. Nicol, M.O. Faure, J.R. Mcneilly, Joël Fontaine, Catherine Taragnat, A.S. Mcneilly

To cite this version:
L. Nicol, M.O. Faure, J.R. Mcneilly, Joël Fontaine, Catherine Taragnat, et al.. Bone morphogenetic protein-4 interacts with activin and GnRH to modulate gonadotrophin secretion in LβT2 gonadotrophs. Journal of Endocrinology, 2008, 196 (3), pp.497-507. 10.1677/jOE-07-0542. hal-02668453

HAL Id: hal-02668453
https://hal.inrae.fr/hal-02668453
Submitted on 31 May 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Bone morphogenetic protein-4 interacts with activin and GnRH to modulate gonadotrophin secretion in LβT2 gonadotrophs

L Nicol*, M-O Faure1*, J R McNeilly, J Fontaine1, C Taragnat1 and A S McNeilly

MRC Human Reproductive Sciences Unit, The Queen’s Medical Research Institute, Centre for Reproductive Biology, 47 Little France Crescent, Edinburgh EH16 4TJ, UK
1UMR 6175 INRA-CNRS-Université de TOURS-Haras Nationaux, Physiologie de la Reproduction et des Comportements, 37380 Nouzilly, France

*Correspondence should be addressed to L Nicol; Email: l.nicol@hrsu.mrc.ac.uk

This is an Open Access article distributed under the terms of the Society for Endocrinology’s Re-use Licence which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

We have shown previously that, in sheep primary pituitary cells, bone morphogenetic proteins (BMP)-4 inhibits FSHβ mRNA expression and FSH release. In contrast, in mouse LβT2 gonadotrophs, others have shown a stimulatory effect of BMPs on basal or activin-stimulated FSHβ promoter-driven transcription. As a species comparison with our previous results, we used LβT2 cells to investigate the effects of BMP-4 on gonadotrophin mRNA and secretion modulated by activin and GnRH. BMP-4 alone had no effect on FSH production, but enhanced the activin+GnRH-induced stimulation of FSHβ mRNA and FSH secretion, without any effect on follistatin mRNA. BMP-4 reduced LHβ mRNA up-regulation in response to GnRH (±activin) and decreased GnRH receptor expression, which would favour FSH, rather than LH, synthesis and secretion. In contrast to sheep pituitary gonadotrophs, which express only BMP receptor types IA (BMPRIA) and II (BMPRII), LβT2 cells also express BMPRIB. Smad1/5 phosphorylation induced by BMP-4, indicating activation of BMP signalling, was the same whether BMP-4 was used alone or combined with activin±GnRH. We hypothesized that activin and/or GnRH pathways may be modulated by BMP-4, but neither the activin-stimulated phosphorylation of Smad2/3 nor the GnRH-induced ERK1/2 or cAMP response element-binding phosphorylation were modified. However, the GnRH-induced activation of p38 MAPK was decreased by BMP-4. This was associated with increased FSHβ mRNA levels and FSH secretion, but decreased LHβ mRNA levels. These results confirm 1. BMPs as important modulators of activin and/or GnRH-stimulated gonadotrophin synthesis and release and 2. important species differences in these effects, which could relate to differences in BMP receptor expression in gonadotrophs.

Journal of Endocrinology (2008) 196, 497–507

Introduction

The gonadotrophins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), are produced by the gonadotroph cells of the anterior pituitary and play important roles in reproductive function. Tight control over the production of these hormones is crucial, particularly in females, to coordinate follicle selection and terminal follicular growth as well as the timing and number of ovulations. Synthesis and release of LH and FSH are regulated by hypothalamic gonadotrophin-releasing hormone (GnRH) and gonadal steroids. Despite these common regulators, divergences in the circulating patterns of LH and FSH are often encountered, suggesting that these regulators act differentially on the production of LH and FSH and/or that other factors are specifically involved in the control of FSH synthesis.

While the pulsatile pattern of GnRH release is essential for the activation and secretion of both gonadotrophs, changes in pulse frequency observed during the oestrous cycle differentially affect the LH and FSH production. High frequencies of GnRH pulses are associated with greater LH secretion whereas lower frequencies favour FSH secretion (Wildt et al. 1981, Dalkin et al. 1989, Kaiser et al. 1997, Molter–Gerard et al. 1999). In addition, the FSH secretion is controlled, independently of LH, by transforming growth factor-β (TGFβ) superfamily members such as activins and inhibins. Activin, a dimer of two highly related β-subunits (βA and/or βB), stimulates FSHβ gene expression and FSH release, whereas inhibin, a heterodimer composed of one α-subunit and one β-subunit (βA or βB), decreases FSH synthesis and release (Carroll et al. 1989). Activin is secreted by the gonads and within the pituitary, where it acts as an autocrine and/or paracrine regulator of FSH synthesis. Recently, other members of the TGFβ superfamily, the bone morphogenetic proteins (BMPs), were shown to modulate preferentially FSH secretion. In ovine pituitary cells, BMP-4 (50 ng/ml) and BMP-6 (100 ng/ml) inhibited FSHβ mRNA expression and FSH release (Faure et al. 2005).
By contrast, in the murine LβT2 gonadotroph cell line and rat pituitary cells, BMP-6 and BMP-7, at higher concentrations (1 μg/ml), BMP-2 and BMP-15 (100 ng/ml) were able to stimulate basal FSH secretion and FSHβ promoter activity (Huang et al. 2001, Otsuka & Shimasaki 2002, Lee et al. 2007). This difference of BMP effect between the mouse and the sheep could reflect a dissimilar pattern of BMP receptors on gonadotroph cells driving different signalling pathways. Alternatively, different BMPs could differentially affect FSH synthesis.

The TGFB superfamily members act through two types of serine/threonine kinase receptors, type I and type II (for review: Miyazawa et al. 2002, Shimasaki et al. 2004). Activin signals through activin receptor types IIA (ActRIIA) or IIB (ActRIIB) and activin receptor type IB (ActRIB, also known as activin receptor-like kinase 4 or ALK-4). Specific BMP signalling requires BMP receptor type II (BMPR-II) and BMP receptor types IA (BMPRIA or ALK-3) or IB (BMPRIB or ALK-6). The ligand-type II receptor complex induces phosphorylation and activation of type I receptors that in turn trans-phosphorylate receptor-activated Smad proteins within the cytoplasm. These then interact with common Smad4, and the resulting complex translocates to the nucleus to affect gene transcription. Activin leads to the specific activation of Smads 2 and 3, whereas BMPs activate Smads 1, 5 and 8. The combinations of activin and BMP ligands and receptors are not unique. For example, ActRIIA and ActRIIB can bind to BMP-6 (Ebisawa et al. 1999), whereas BMPRIB binds specifically to BMP ligands (Liu et al. 1995, Nohno et al. 1995). Regarding type I receptors, ActRIA (also known as ALK-2) has been identified as a type-I receptor for BMPs (Macias-Silva et al. 1998).

To further explore BMP action at the gonadotroph cell level, we have examined the effects of BMP-4 on mouse LβT2 cell LH and FSH β-subunit mRNA levels and gonadotrophin release. Considering that activin and GnRH are important modulators of FSH synthesis, it is of interest to determine if BMP-4 interacts with these two factors and to explore the signalling pathways through which BMP-4 exerts its effect.

Materials and Methods

Cell culture

Mouse LβT2 cells (provided by Dr P Mellon, University of California, San Diego, CA, USA) were routinely maintained in Dulbecco’s modified Eagle’s medium (DMEM) with 10% foetal calf serum (HyClone, Logan, UT, USA) on flasks coated with Matrigel (1:29; BD Biosciences Clontech, Cowley, Oxford, UK). For experimental purposes LβT2 cells were set up as described previously (Nicol et al. 2004) at a density of 2·75×10⁵/well. After overnight incubation, cells were treated with 0 or 50 ng/ml recombinant human activin A (R&D Systems, Abingdon, Oxon, UK) ± a daily 1-h pulse of 10 nM GnRH (Bachem, St Helens, Merseyside, UK), in the presence or absence of 50 ng/ml recombinant human BMP-4 (R&D Systems) for 3 days. Media were collected daily for measurement of secreted FSH and LH by RIA. On day 4, total RNA was extracted from cells for the measurement of FSHβ, LHβ, GnRH receptor (GnRH-R) and follistatin mRNA levels by quantitative RT-PCR. In addition, on day 4, after a final pulse of GnRH, protein extracts were prepared for western blot analysis.

Mouse FSH and LH RIAs

RIAs for mouse FSH and LH were performed as previously described (McNeilly et al. 1996), using reagents supplied by Dr A Parlow (NHPP, Harbor-UCLA, Torrance, CA, USA). The minimum detectable concentrations were 1 ng/ml and 200 pg/ml for FSH and LH respectively. The intra- and inter-assay coefficients of variation were <10% for both assays.

Qualitative RT-PCR

The expression of BMP receptor mRNA in LβT2 cells was assessed by RT-PCR, using adult mouse pituitary as a positive control. Total RNA was extracted using TRI Reagent (Sigma-Aldrich Ltd). Aliquots were treated with DNase I using DNA-free (Ambion (Europe) Ltd, Huntingdon, Cambs, UK) and reverse transcribed, using random hexamers, with Taqman Reverse Transcription reagents (PE Biosystems, Warrington, Cheshire, UK) according to manufacturers protocol. PCR was performed for 35 cycles using ThermoStart Taq DNA polymerase (Abgene, Epsom, Surrey, UK). Primer sequences were as follows: BMPRIA: fwd: CCTGTTGTTATAAGGCTCGTT; rev: TCTCCT-ACTGGAATAATGC; BMPRIB: fwd: AGATTGGAAAGGCCTGATG; rev: GATGTCAACCTCATTTGTGAAG-TGTC; BMPRII: fwd: GAGACTGGCATTATCTTCAC; rev: AGCTCCTTCTAGCCTTCTG. Predicted product sizes were 194, 473 and 245 bp respectively.

Immunostaining

LβT2 cells, cultured on Labtek II chamber slides (Fisher Scientific UK, Manchester, UK) were washed with PBS, fixed in Bouin’s solution for 5 min, washed and then permeabilized using 10% normal goat serum, 1% BSA in PBS (blocking solution) containing 0·2% Igepal CA-630 for 20 min at room temperature. After washing, cells were blocked for 1 h, then incubated at 4 °C overnight with rabbit polyclonal antibodies directed against BMPRIA, BMPRIB (ten Dijke et al. 1994) or BMPRII (Rosenzweig et al. 1995), diluted at 1:50. Antibodies were kindly donated by Dr C-H Heldin (Ludwig Institute for Cancer Research, Uppsala, Sweden). Negative controls were performed with 1:100 goat serum in place of the primary antibody. Slides were washed and then incubated at room temperature for 1 h with goat anti-rabbit Alexa 488 (Molecular Probes, Eugene, OR, USA)
Levels of mRNA for FSHβ, LHβ, GnRH-R, and follistatin were measured using Taqman RT-PCR. Primer and probe sequences were designed using Primer Express software and synthesized by PE Biosystems or by Biosource Europe SA (Nivelles, Belgium). FSHβ, LHβ and GnRH-R primer/probe sequences have been previously reported (Nicol et al. 2004). The sequences for follistatin were as follows: fwd: GGGCTGGATGGAAAAACCTA; rev: CGGCTGCTC-TTTGCATCTGT; probe (FAM labelled): CGCAAC-GAATGTCACCCTCCTACAAGG. Ribosomal 18S primers and probe were from a Taqman Ribosomal RNA Control Reagents kit (VIC labelled probe). RNA was prepared, DNase I-treated and reverse transcribed as described above. RNA was added to RT reactions at 10 ng/μl. A PCR mix was prepared, consisting of Taqman Universal PCR Master Mix (1×), gene specific forward and reverse primers (300 nM each) and probe (200 nM), and ribosomal 18S forward and reverse primers (50 nM each) and probe (200 nM). This was aliquoted into tubes, then cDNA was added at 1 μl/25 μl reaction mix. Aliquots (25 μl) were transferred to wells in a 96-well PCR plate, with each sample run in duplicate. Plates were sealed with optical adhesive covers and the PCRs run on ABI Prism 7900HT PCR machine using standard conditions. Controls included cDNA prepared with omission of reverse transcriptase. Prior to analysis, a validation assay was performed to demonstrate that amplification of target genes and the reference (18S) were approximately equal. Quantification of specific mRNA levels was performed by the ΔΔCt method (Bulletin no.2; PE Biosystems). Standard PCRs using each set of primers were run on an agarose gel to confirm amplification of a single product of the correct size. Unless otherwise stated all reagents, equipment and software were from PE Biosystems.

Western blotting

To investigate activation of Smads, ERK1/2, p38 MAPK and cAMP response element–binding protein (CREB), LβT2 cells were treated as described above except that on day 4, a final pulse of GnRH was given (duration of 1 h for Smad study and 10 or 20 min for ERK1/2, p38 and CREB studies). The cells were then washed with ice-cold PBS and lysed in buffer containing 10 mM Tris (pH 7-4), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 0-5% Igepal CA-630, 100 mM sodium fluoride, 10 mM sodium pyrophosphate, 10 mM sodium orthovanadate, protease inhibitor cocktail. The protein concentration was determined using a Bio-Rad DC protein assay (Bio-Rad Laboratories Ltd).

After 5 min at 95°C in reducing buffer, proteins were separated on SDS-PAGE gels and electroblotted onto Immobilon membranes (Millipore Corporation, Bedford, MA, USA). For Smad and ERK analysis, membranes were blocked for 1 h at room temperature in Tris-buffered saline, 0-1% Tween (TBST) containing 5% fat-free dry milk and then incubated in primary antibody overnight at 4°C. The P-Smad1/5 rabbit monoclonal, P-ERK1/2 and total ERK1/2 polyclonal antibodies were from Cell Signaling Technology (Danvers, MA, USA) and were all used at 1:1000 dilution. The Smad1/5 and Smad2/3 polyclonal antibodies were from Upstate Biotechnology (Lake Placid, NY, USA) and were used at 1:500 and 1:1000 dilutions respectively. The P-Smad2/3 antibody was provided by Dr C-H Heldin (Ludwig Institute for Cancer Research, Uppsala, Sweden) and used at 1:2000 dilution. After washing in TBST, the membranes were incubated with Amersham ECL peroxidase-labeled anti-rabbit antibody (GE Healthcare UK Ltd, Little Chalfont, Bucks, UK) for 1 h at room temperature. Immunoreactive proteins were detected using Amersham ECL Plus western blotting detection reagents and exposure to Hyperfilm ECL (both from GE Healthcare UK Ltd). For quantification, the membranes were scanned on a Typhoon 9400 variable-mode imager (GE Healthcare UK Ltd). In each case, the membrane was probed first with the antibody against the phosphorylated protein, then stripped using buffer containing 2% SDS, 62.5 mM Tris (pH 6.8), 0-1 M 2-mercaptoethanol for 30 min at 75°C. After washing, immunodetection was repeated using antibody against the total protein. For P-p38 and P-CREB analysis, membranes were blocked in Odyssey blocking buffer (Licor Biosciences UK Ltd, Cambridge, UK) and primary antibodies were diluted in Odyssey buffer diluted 1:1 with PBS, 0-1% Tween 20 (PBST). The primary antibody against the phosphorylated protein was combined with a monoclonal anti–α-tubulin to act as loading control for quantitation. The P-p38 and P-CREB antibodies (Cell Signaling Technology) were used at 1:1000 dilutions and α-tubulin monoclonal (Sigma) was used at 1:3000 dilutions. After washing in PBST the membranes were incubated with a mixture of goat anti-rabbit IR Dye 680 and goat anti-mouse IR Dye 800CW for 1 h at room temperature. Immunoreactive proteins were detected and quantified using an Odyssey Infrared Imaging System (Licor Biosciences UK Ltd).

Statistical analysis

Results are reported as mean ± S.E.M. from one representative experiment. Experiments were carried out at least three times. Analyses of interactions between BMP-4 and other treatment groups were carried out using two-way ANOVA and the Bonferroni method. Comparisons between treatments on FSH, LH concentrations, FSHβ and LHβ mRNA levels and phosphorylated protein intensities were analysed by one-way ANOVA followed by Tukey's multiple comparison test. The value of P<0.05 was considered significant.
The statistical analyses were performed using GraphPad Prism version 4.00 (GraphPad Software, San Diego, CA, USA).

Results

Expression of BMP receptors in LβT2 gonadotrophs and adult mouse pituitary

Qualitative RT-PCR analysis of total RNA prepared from mouse LβT2 gonadotroph cells and adult mouse pituitary was carried out using primers specific for BMPRIA (ALK-3), BMPRIB (ALK-6) and BMPRII. As shown in Fig. 1A, products of the expected size were observed for all three receptor types in both LβT2 cells and adult mouse pituitary. In negative controls, performed by omitting reverse transcriptase enzyme in RT reactions, no PCR products were detected (not shown). Particularly in LβT2 cells, the levels of BMPRIB mRNA appeared to be lower than the other two receptor types. Immunostaining using specific antibodies confirmed the presence of expressed protein for all three BMP receptor types in LβT2 cells when compared with a negative control (Fig. 1B).

Effects of BMP-4 on gonadotrophin secretion and FSHβ and LHβ mRNA expressions

To determine whether BMP-4 was capable of modifying gonadotrophin production and secretion in LβT2 gonadotrophs, cells given activin ± a daily 1 h pulse of GnRH for three days were also treated with BMP-4. Secretion profiles for FSH and LH, representing the total protein secreted during day 3 GnRH treatment and the subsequent overnight incubation, and the corresponding day 4 β-subunit mRNA levels are shown in Fig. 2. As expected, FSH secretion increased \( (P<0.001) \) in response to activin and this effect was increased synergistically \( (P<0.001) \) in the presence of GnRH, although GnRH alone had no effect (Fig. 2A). While BMP-4 alone had no effect on FSH secretion, it increased the release of FSH in response to activin and activin + GnRH \( (P<0.001\) and \( P<0.001 \) respectively). Similarly, the FSHβ mRNA expression was up-regulated by activin \( (P<0.05) \) and this effect was also increased synergistically by GnRH \( (P<0.001; \) Fig. 2B). BMP-4 alone, or in combination with activin or GnRH, had no effect on FSHβ mRNA, but it further increased activin + GnRH-stimulated mRNA levels \( (P<0.01) \).

LH release from LβT2 cells was stimulated by GnRH \( (P<0.001) \) and these levels almost doubled when GnRH was combined with activin \( (P<0.001, \) Fig. 2C). BMP-4 alone or in combination with activin and/or GnRH did not affect LH release. By contrast, while LHβ mRNA expression also increased in response to GnRH and activin + GnRH \( (P<0.001) \), these levels were reduced \( (P<0.05) \) by BMP-4 (Fig. 2D).

Effects of BMP-4 on GnRH-R and follistatin mRNA levels

To investigate the possible underlying mechanisms for the effects of BMP-4 on gonadotrophin production and release in LβT2 gonadotrophs, GnRH-R and follistatin mRNA levels on day 4 from cells treated as described were measured. As shown in Fig. 3A, activin and GnRH alone produced small increases in GnRH-R mRNA levels, but combined activin + GnRH was required to achieve a significant \( (P<0.001) \) effect. BMP-4 reduced GnRH-R mRNA expression in both the GnRH- and activin + GnRH-treated cells \( (P<0.01 \) and \( P<0.001 \) respectively). Follistatin mRNA levels, on the other hand, increased in response to activin and activin + GnRH \( (P<0.01 \) and \( P<0.001 \) respectively, Fig. 3B). BMP-4 treatment significantly reduced the activin-stimulated increase in follistatin mRNA \( (P<0.05) \), but had no effect on the increase observed in response to activin + GnRH.

Activation of Smad signalling pathways by BMP-4 and activin

To determine whether or not the BMP and activin signalling pathways could interact at the Smad activation level, LβT2 cells cultured in the presence or absence of activin ± a daily 1 h pulse of GnRH for 3 days were also exposed to BMP-4. On day 4, a final 1-h pulse of GnRH was given and proteins extracted for western blot analysis, using antibodies specific for P-Smad1/5 and P-Smad2/3, to look at the BMP and activin signalling pathways respectively. As shown in Fig. 4A, BMP-4, but not activin, induced the appearance of a band at \( \sim 60 \) kDa, corresponding to the phosphorylated form of Smad1/5. The presence of activin and/or GnRH with BMP-4 did not affect the intensity of this band when compared with BMP-4 treatment alone. By contrast, activin (± GnRH) induced activation of Smad2/3 as indicated by increased intensity of band(s) at \( \sim 55–58 \) kDa corresponding to phosphorylated Smad2/3 (Fig. 4B). When cells were treated with both BMP-4 and activin ± GnRH, band intensity did not change compared with activin ± GnRH alone. It should be noted that the results shown here were obtained using an antibody against P-Smad2/3 and that two bands were observed. However, it appeared that the upper band (P-Smad2) was mainly responsible for the increased signal in response to activin ± GnRH and indeed, identical results were obtained using an antibody specific for P-Smad2 (data not shown).

Effects of BMP-4 on the GnRH-induced activation of ERK1/2, p38 MAPK and CREB

As there is evidence that, as well as signalling through the Smad pathways, TGFβ family members may also utilize other downstream signalling pathways, we examined whether or not BMP-4 activated or influenced the activation of other pathways known to be active in gonadotrophs. The LβT2 cells were cultured in the presence or absence of activin ± a daily 1-h pulse of GnRH ± BMP-4 for 3 days.
On day 4, a 10- or 20-min pulse of GnRH was given to cells previously exposed to GnRH and proteins extracted for western blot analysis, using antibodies specific for the phosphorylated forms of ERK1/2, p38 MAPK and CREB. As expected, GnRH induced ERK1/2 phosphorylation, with the same effect observed in the presence and absence of activin (P<0.001; Fig. 5A). BMP-4 had no effect on ERK activation. The results shown here were from cells that are given GnRH for 20 min on day 4. After 10-min GnRH supply the same trend was observed, but the result did not

Figure 1 Expression of BMP receptors. (A) mRNAs for BMP receptors IA, IB and II were detected in untreated LβT2 cells and adult mouse pituitary by RT-PCR at 35 cycles. (B) BMP receptor proteins IA, IB and II were detected in untreated LβT2 cells by immunofluorescence. Bar represents 10 μm.
reach significance (data not shown). As shown in Fig. 5B, p38 MAPK was also activated by GnRH \((P<0.01)\), but in this case activin increased the response observed with GnRH alone \((P<0.05)\). BMP-4 treatment, in the presence of activin + GnRH, reduced phosphorylated p38 levels \((P<0.01)\). In this case, the treatment 10-min GnRH supply gave the optimum result, as after 20 min GnRH levels of phosphorylated p38 were unmeasurable in our detection system. CREB was activated by GnRH alone \((P<0.001;\) Fig. 5C) and neither activin nor BMP-4 had a significant effect. Again, 20-min GnRH produced the optimum result, although after 10 min a statistically similar effect was observed (data not shown).

**Discussion**

Earlier studies have identified BMPs as modulators in the regulation of FSH synthesis and release. In rodent primary pituitary cells and the mouse LβT2 gonadotroph cell line, different BMPs (BMP-15, as well as BMP-6 and -7 at high doses) exert a stimulatory effect on FSHβ transcription (Huang et al. 2001, Otsuka & Shimasaki 2002), whereas in ovine primary pituitary cells, BMP-4 and BMP-6 have inhibitory effects on FSHβ mRNA expression and FSH release (Faure et al. 2005).

In the present study we report that, in LβT2 mouse gonadotroph cells, BMP-4 alone had no effect on FSHβ mRNA and FSH release, as reported previously for BMP-2, -6 and -7 used at comparable doses (Huang et al. 2001, Lee et al. 2007). Remarkably, BMP-4 increased both FSHβ mRNA and FSH secretion when combined with activin A and GnRH. Recent studies observed synergistic effects on FSHβ transcription between BMP-2 and activin A in LβT2 cells (Lee et al. 2007). Moreover, our data show for the first time that LHβ mRNA and LH secretion remained unaffected by BMP-4 treatment but that, interestingly, the up-regulation of LHβ mRNA in response to GnRH was reduced.

Our results underline the opposite actions of BMP-4 on FSH expression in ewe primary pituitary cells and murine homogeneous gonadotroph cells. In ewe pituitary cells BMP-4 and BMP-6 decreased both basal and
activin-stimulated FSHβ mRNA levels and FSH release (Faure et al. 2005). The reasons for this differential effect are not clear. They may reflect different specific patterns of BMP receptors between ewe gonadotroph cells and LβT2 cells leading to activation of different signalling pathways and/or different intra-cellular components. The present results demonstrate that LβT2 cells express mRNAs encoding the BMP receptors BMPRIA, BMPRIB and BMPRII, confirming data from Lee et al. (2007), in contrast to another study in which only BMPRIA and BMPRII were found (Otsuka & Shimasaki 2002). However, in our study, BMPRIB mRNA does appear to be expressed at lower levels than BMPRIA and BMPRII. Furthermore, immunocytochemistry confirmed the presence of proteins corresponding to the three types of receptors. In contrast to LβT2 cells, BMPRIB was not detected in ewe gonadotroph cells (Faure et al. 2005). The bioavailability of different receptors could dictate the FSH response to BMPs. Even if...
BMP-4 is able to bind complexes of BMPRII and BMPRIA or BMPRIIB (ten Dijke et al. 1994), the two receptors may not be equivalent in activating signalling. Alternatively, receptors other than BMPRIA or IB could be involved. A previous report has shown that BMP-2 acts through BMPRII and ALK-2 in LβT2 cells (Lee et al. 2007). Moreover, ewe primary pituitary cells are composed of different cell types and the target cell type(s) for BMP-4 are not known. Whether BMP-4 acts directly on gonadotroph cells in sheep primary pituitary cells has yet to be determined.

The nature of the mechanisms by which BMP-4 interacts with activin and GnRH is still unclear. The classical signalling pathway used by BMPs involves Smads 1, 5 and 8 activated by BMP receptors type II and type I. As demonstrated by the phosphorylation of Smad1/5, BMP-4 activated the BMP pathway in LβT2 cells. However, BMP-4 alone failed to modify the level of FSHβ or LHβ mRNA and gonadotrophin release. It is possible that Smads 1/5 mediate other responses to BMP in LβT2 cells such as cell proliferation (Otsuka & Shimasaki 2002, Takeda et al. 2007). BMP-4 action required the presence of activin and was amplified when GnRH was added in combination with activin. This action was not accompanied by changes in the level of P-Smad1/5, suggesting that other signalling proteins and/or pathways are involved. A recent study suggested that Smad8 might be the preferred signalling protein in the BMP pathway since overexpression of Smad8, but not Smad1 or 5, enhanced the FSHβ promoter activity in response to BMP-2 (Lee et al. 2007). It is possible that BMP-4 may be acting through the modulation of activin and/or GnRH pathway. Previous data have shown that activin transmits its signal through Smad2 and/or Smad3 phosphorylation (Dupont et al. 2003, Suszko et al. 2003, Bernard 2004). While we detected an increase in the phosphorylated forms of Smad2/3 in the presence of activin, the addition of BMP-4 + GnRH in LβT2 cell medium did not change the level of P-Smad2/3. Thus, the interaction between BMP-4, activin and GnRH does not modify Smad1/5 or Smad2/3 phosphorylation.

It is unclear whether follistatin plays a role in this system, as the effects of BMP-4 on expression of follistatin mRNA were inconsistent. Activin-stimulated mRNA was reduced by BMP-4 treatment, in contrast to activin + GnRH-stimulated mRNA which remained unaffected. In addition, increased follistatin synthesis did not have any effect on Smad2/3 phosphorylation.

Figure 5 Activation of ERK, p38 MAPK and CREB signalling. The LβT2 cells were cultured with 0 or 50 ng/ml BMP-4 in the presence of 50 ng/ml activin A ± a daily 1-h pulse of 10 nM GnRH for 3 days. On day 4, the cells were given a final GnRH pulse for 10 or 20 min and levels of (A) phosphorylated ERK1/2 expressed relative to total ERK1/2, (B) phosphorylated p38 expressed relative to α-tubulin and (C) phosphorylated CREB expressed relative to α-tubulin were measured by western blotting. Different letters indicate significant differences between treatment groups. Data shown for ERK1/2 and CREB are from 20-min GnRH treatment groups and for p38 from the 10-min GnRH treatment. Values represent means ± S.E.M. from one representative experiment; n = 2.
phosphorylation. However, it should be emphasized that the activin and BMP-4 levels used in this study would most likely be sufficient to completely override any possible effects of endogenous follistatin, which may be more relevant in vivo, where levels of endogenous activin and BMPs would be lower. The ability of follistatin to bind BMPs, albeit with a lower affinity than activin (Balemans & Van Hul 2002), suggests it may well be involved in the BMP-mediated regulation of FSH production in vivo.

Since there is evidence that BMPs can operate through Smad-independent pathways such as MAPK signalling molecules (Lou et al. 2000, Xiao et al. 2002, Derynck & Zhang 2003), changes in levels of phosphorylated ERK1/2 and p38 were measured. As expected, GnRH activated the phosphorylation of ERK1/2 (Liu et al. 2002), but this response was not modified by activin, corroborating previous data (Gregory et al. 2005). The presence of BMP-4 did not affect GnRH-mediated activation of ERK1/2. Previous studies have shown that BMPs can induce the p38 MAPK-dependent pathway (Iwasaki et al. 1999, Nakamura et al. 1999). In the current study we observed that the level of GnRH-enhanced p38 activation was increased by activin, confirming a previous report (Coss et al. 2007), and this correlated with increased FSHβ mRNA and FSH secretion. This p38 activation in response to GnRH+activin was reduced by BMP-4, contrary to the increase in FSHβ mRNA and FSH secretion. As GnRH alone induced the p38 activation, but had no effect on FSHβ mRNA and FSH secretion, which remained equivalent to those in untreated cells, the exact role of p38 in regulating FSH production is unclear. The BMP-induced reduction in p38 MAPK does, however, correlate with a decrease in LHβ mRNA expression. GnRH is also known to activate CREB protein in gonadotroph cell lines (Duan et al. 1999, Shafiee-Kermani et al. 2007). Our results confirm that GnRH activates CREB, but CREB phosphorylation was not significantly affected by activin and/or BMP-4. Our current data, therefore, indicate that the classical upstream activin (Smad2/3) or GnRH (ERK, CREB) pathways are not modified in the presence of BMP-4. The p38 MAPK signalling appears to be modulated by BMP-4, but whether this has direct effects on FSH production/secretion remains to be determined. Considering the synergistic effects of BMP-2 and activin on FSHβ transcription in LβT2 cells, it has recently been suggested that each ligand employs different, non-overlapping mechanisms to generate their effects (Lee et al. 2007). A summation of the independent signalling pathways activated by BMP-4, activin and GnRH could mediate their combined response with an amplified action occurring specifically at the level of the FSHβ promoter. So far, it is not known if BMP-4 exerts its effect directly on the FSHβ promoter and detailed analyses will be necessary to localize the site of BMP action.

In addition to its effect on FSHβ mRNA and FSH release, BMP-4 also regulated LHβ expression. In the present study, we obtained clear evidence that BMP-4 decreased levels of GnRH and activin-induced LHβ mRNA. This effect appeared to be mediated, at least partly, by the down-regulation of GnRH-R mRNA. The inhibitory effect of BMP-4 on LHβ and GnRH-R mRNA levels is contradictory to the stimulatory action of activin (Pernasetti et al. 2001, Nicol et al. 2004, Yamada et al. 2004). Several studies indicate a correlation between GnRH-R density and a differential gonadotrophin response to GnRH (Kaiser et al. 1995, Bedecarrats & Kaiser 2003). High levels of GnRH-R are associated with preferential LHβ gene expression whereas lower levels favour the stimulation of FSHβ gene expression, suggesting a role for GnRH-R levels in mediating these differential responses. Thus, we propose that BMP-4, partly by inhibiting GnRH-R expression, could induce an inhibition of the LHβ mRNA level, potentially through p38 MAPK activation, and promote an increase in the level of FSHβ mRNA and FSH release. The absence of any effect of BMP-4 on LH release compared with its effect on LHβ mRNA levels may simply reflect the release of stored LH via the regulated secretory pathway (Nicol et al. 2002, 2004).

In conclusion, our results show that BMP-4, activin and GnRH act in a synergistic manner to up-regulate FSHβ mRNA and FSH release. By contrast, BMP-4 reduces the GnRH and/or activin-induced up-regulation of LHβ and GnRH receptor mRNA. We demonstrated that the classical upstream BMP signalling molecule(s) are activated in the LβT2 cells by BMP-4, but other signalling molecules/pathways must be involved in order to obtain the effects on FSH production observed in response to the interaction of BMP-4 with activin/GnRH. Naturally, these results need to be checked in primary cell cultures to determine if the difference in the effects of BMP-4 in the present mouse LβT2 gonadotroph cell line and our previous studies in sheep primary cells is due to different paracrine or autocrine mechanisms involving an interaction with other pituitary cell types. In contrast to mouse pituitary, BMP-4 mRNA was not detected in LβT2 cells (Lee et al. 2007, our unpublished data) arguing for a paracrine role. Collectively, the present data reinforce the concept of a role for BMP-4 in the control of FSH and reveal a novel involvement in LH control.

Acknowledgements

We would like to thank Dr P Mellon for providing the LβT2 cells, Dr A Parlow and NHPP for providing RIA reagents and Dr C-H Heldin for the gift of BMP receptor antibodies.

Disclosure

This study was supported by the Medical Research Council. The authors declare that there is no conflict of interest that would prejudice the impartiality of this work.
References

Balemans W & Van Hul W 2002 Extracellular regulation of BMP signaling in vertebrates: a cocktail of modulators. Developmental Biology 250 231–250.

Bedecarrats GY & Kaiser UB 2003 Differential regulation of gonadotrophin subunit gene promoter activity by pulsatile gonadotropin-releasing hormone (GnRH) in perfused LβT2 cells: role of GnRH receptor concentration. Endocrinology 144 1802–1811.

Bernard DJ 2004 Both SMAD2 and SMAD3 mediate activin-stimulated expression of the follicle-stimulating hormone β subunit in mouse gonadotrope cells. Molecular Endocrinology 18 606–623.

Carroll RS, Corrigan AZ, Gharib SD, Vale W & Chun WW 1989 Inhibin, activin, and follistatin: regulation of follicle-stimulating hormone messenger ribonucelic acid levels. Molecular Endocrinology 3 1969–1976.

Coss D, Hand CM, Yaphockun KKJ, Ely HA & Mellon PL 2007 p38 Mitogen-activated protein kinase is critical for synergetic induction of the FSHβ gene by gonadotropin-releasing hormone and activin through augmentation of c-fos induction and smad phosphorylation. Molecular Endocrinology 21 3071–3086.

Dalkin AC, Haisenleder DJ, Ortolano GA, Ellis TR & Marshall JC 1989 The frequency of gonadotropin-releasing-hormone stimulation differentially regulates gonadotrophin subunit messenger ribonucelic acid expression. Endocrinology 125 917–924.

Derynck R & Zhang YE 2003 Smad-dependent and Smad-independent signaling in vertebrates: a cocktail of modulators. Nature 425 577–584.

Duan WR, Shin J & Jameson JL 1999 Estradiol suppresses phosphorylation of cyclic adenosine 3’, 5’-monophosphate response element binding protein (CREB) in the pituitary: evidence for indirect action via gonadotrophin-releasing hormone. Molecular Endocrinology 13 1338–1352.

Dupont J, McNeilly J, Vaiman A, Canepa S, Combarbous Y & Taragnot C 2003 Activin signaling pathways in TGF-beta family signalling. Nature 425 577–584.

Eibasawa T, Tada K, Kitajima I, T ojo K, Sampath TK, Kawabata M, Miyazono K & Iwasaki S, Iguchi M, W atanabe K, Hoshino R, Tsujimoto M & Kohno M 1994 Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. Journal of Biological Chemistry 274 16985–16988.

Faure M-O, Nicol L, McNeilly JR, Stridsberg M & McNeilly AS 2004 Differential regulation of the gonadotrophin subunit and GnRH receptor messenger ribonucelic acid levels in ovine pituitary cells. Journal of Endocrinology 186 109–121.

Gregory SJ, Lacz CT, Detz AA, Xu S, Petroillo LA & Kaiser UB 2005 Synergy between activin A and gonadotrophin-releasing hormone in transcriptional activation of the rat follicle-stimulating-hormone-beta gene. Molecular Endocrinology 19 237–254.

Huang HJ, Wu JC, Su II, Zhuang O & Miller WL 2001 A novel role for bone morphogenetic proteins in the synthesis of follicle-stimulating hormone. Endocrinology 142 2275–2283.

Iwasaki S, Iuchi M, Watanabe K, Hoshino R, Tsujimoto M & Kohno M 1999 Specific activation of the p38 mitogen-activated protein kinase signaling pathway and induction of neurite outgrowth in PC12 cells by bone morphogenetic protein-2. Journal of Biological Chemistry 274 26503–26510.

Kaiser UB, Sabbagh E, Katzenellenbogen RA, Conn PM & Chin WW 1995 A mechanism for the differential regulation of gonadotrophin subunit gene expression by gonadotrophin-releasing hormone. PNAS 92 12280–12284.

Kaiser UB, Jakubowiak A, Steinberger A & Chin WW 1997 Differential effects of gonadotrophin-releasing hormone (GnRH) pulse frequency on gonadotrophin subunit and GnRH receptor messenger ribonucelic acid levels in vitro. Endocrinology 138 1224–1231.

Lee KB, Khiransara V, Santos MM, Lamba P, Yuen T, Salfon SC & Bernard DJ 2007 Bone morphogenetic protein 2 and activin A synergistically stimulate follicle-stimulating hormone beta subunit transcription. Journal of Molecular Endocrinology 38 315–330.

Liu F, Ventura F, Doody J & Massague J 1995 Human type II receptor for bone morphogenetic proteins (BMPs): extension of the two-kinase receptor model to the BMPs. Molecular and Cellular Biology 15 3479–3486.

Liu F, Austin DA, Mellon PL, Olefsky JM & Webster NJ 2002 GnRH activates ERK1/2 leading to the induction of c-fos and LHB protein expression in LβT2 cells. Molecular Endocrinology 16 419–434.

Lou J, Ti Y, Li S & Manske PR 2000 Involvement of ERK in BMP-2 induced osteoblastic differentiation of mesenchymal progenitor cell line C3H10T1/2. Biochemical and Biophysical Research Communications 268 757–762.

Macki-K, Shinozaki M, Har T, Furuya T & Miyazono K 2002 Transgenic Smad pathways in TGF-β superfamily signalling. Genes to Cells 7 1191–1204.

Molet-Gerard C, Fontaine J, Guerin S & Taragnot C 1999 Differential regulation of the gonadotrophin storage pattern by gonadotrophin-releasing hormone pulse frequency in the ewe. Biology of Reproduction 60 1224–1230.

Nakamura K, Shira T, Morishita S, Uchida S, Sacki-Mura K & Maki shima F 1999 p38 mitogen-activated protein kinase functionally contributes to chondrogenesis induced by growth/differentiation factor-5 in ATDC5 cells. Experimental Cell Research 250 351–363.

Nicol L, McNeilly JR, Strudberg M, Crawford JL & McNeilly AS 2002 Influence of steroids and GnRH on biosynthesis and secretion of secretogranin II and chromogranin A in relation to LH release in LβT2 gonadotroph cells. Journal of Endocrinology 174 473–483.

Nicol L, McNeilly JR, Strudberg M & McNeilly AS 2004 Differential secretion of gonadotrophins: investigation of the role of secretogranin II and chromogranin A in the release of LH and FSH in LβT2 cells. Journal of Molecular Endocrinology 32 467–480.

Nomoto T, Ishikawa T, Satoh T, Hosokawa K, Noji S, Wolsing DH & Rosenbaum JS 1995 Identification of a human type II receptor for bone morphogenetic protein-4 that forms differential heterocomplexes with bone morphogenetic protein type I receptors. Journal of Biological Chemistry 270 22522–22526.

Otsuka F & Shimasaki S 2002 A novel function of bone morphogenetic protein-15 in the pituitary: selective synthesis and secretion of FSH by gonadotropes. Endocrinology 143 4938–4941.

Pernasetti F, Vasilyev VV, Rosenberg SB, Bailey JS, Huang HJ, Miller WL & Mellon PL 2001 Cell-specific transcriptional regulation of follicle-stimulating hormone-β by activin and gonadotrophin-releasing hormone in the LβT2 pituitary gonadotrope cell model. Endocrinology 142 2284–2295.

Rosenzweig BL, Imamura T, Okadome T, Cox GN, Yamashita H, ten Dijke P, Heldin CH & Miyazono K 1995 Cloning and characterization of a human type II receptor for bone morphogenetic proteins. PNAS 92 7632–7636.

Shafiee-Kermani F, Han SO & Miller WL 2007 Chronic gonadotrophin-releasing hormone inhibits activin induction of the ovine follicle-stimulating hormone beta-subunit: involvement of 3’, 5’-cyclic adenosine monophosphate response element binding protein and nitric oxide synthase type I. Endocrinology 148 3346–3355.

Shimasaki S, Kelly Moore R, Otsuka F & Erickson GF 2004 The bone morphogenetic protein system in mammalian reproduction. Endocrine Reviews 25 732–801.

Suszko MI, Lo DJ, Suh H, Camper SA & Woodruff TK 2003 Regulation of the rat follicle-stimulating hormone β-subunit promoter by activin. Molecular Endocrinology 17 318–332.

Journal of Endocrinology (2008) 196, 497–507

www.endocrinology-journals.org
Takeda M, Otsuka F, Otani H, Inagaki K, Miyoshi T, Suzuki J, Mimura Y, Ogura T & Makino H 2007 Effects of peroxisome proliferator-activated receptor activation on gonadotrophin transcription and cell mitosis induced by bone morphogenetic proteins in mouse gonadotrope LβT2 cells. *Journal of Endocrinology* 194: 87–99.

Wildt L, Hausler A, Marshall G, Hutchison JS, Plant TM, Belchetz PE & Knobil E 1981 Frequency and amplitude of gonadotrophin-releasing hormone stimulation and gonadotrophin secretion in the rhesus monkey. *Endocrinology* 109: 376–385.

Xiao G, Gopalakrishnan R, Jiang D, Reith E, Benson MD & Franceschi RT 2002 Bone morphogenetic proteins, extracellular matrix, and mitogen-activated protein kinase signaling pathways are required for osteoblast-specific gene expression and differentiation in MC3T3-E1 cells. *Journal of Bone and Mineral Research* 17: 101–110.

Yamada Y, Yamamoto H, Yonehara T, Kanasaki H, Nakanishi H, Miyamoto E & Miyazaki K 2004 Differential activation of the luteinizing hormone β-subunit promoter by activin and gonadotrophin-releasing hormone: a role for the mitogen-activated protein kinase signaling pathway in LβT2 gonadotrophs. *Biology of Reproduction* 70: 236–243.

Received in final form 20 December 2007
Accepted 4 January 2008
Made available online as an Accepted Preprint 4 January 2008